Human cytomegalovirus GB polypeptide
US11857622B2 · kind B2 · utility
0Cited by
5References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2021 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Jun 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.